Revolution Medicines

Senior Director, HEOR/RWE - GI

Remote (United States) · Director · Full-time

Sponsorship not specified$10k-$13kDetected 1 day ago

CompliancePatient CareResearchLeadershipCommunication

About the role

They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions.
The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally.
The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans.

Develops and evolves product HEOR/RWE strategy, including integration with development and market access planning.
Delivers HEOR/RWE tactics with quality and in alignment with agreed upon timing.
Leads enterprise partnerships with payers, HTA agencies, and global consortia to help shape access strategy, policies, evidence standards, and evidence generation activities.

Experience in oncology HEOR and RWE development.
Minimum 10-13 years of relevant experience with an advanced degree in a relevant field (MD, PhD, PharmD).
Track record of high impact publications in HEOR/RWE topics.
Proven success influencing payer/HTA strategy and incorporating HEOR considerations into clinical development programs.
Strong written and interpersonal communication skills, with an ability to present complex technical information clearly.
Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models.
Ability to establish relationships with experts in real world evidence (RWE) and therapeutic areas of interest.
10+ years of relevant experience in the pharmaceutical/biotech industry.
Global launch experience.
Experience related to gastrointestinal oncology.
#LI-Remote #LI-VN1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below.

$232,000 - $290,000 USD
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process.

Aligns with Medical Affairs and Development leadership to design research and delivers evidence consistent with the medical strategy and IEP.
Works with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams.
Provides HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies.
Facilitates the communication of the value proposition of Revolution Medicines' portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions.
Facilitates and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care.
They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.